论文部分内容阅读
慢性粒细胞白血病(CML)是起源于造血干细胞的恶性克隆性疾病。约90%～95%CML患者具有费城染色体(Philadelphia,Ph),其分子基础是9号染色体上的c-abl基因易位到22号染色体上的bcr基因上形成新的基因嵌合体-bcr/abl融合基因,即t(9;22)(q34;q11)。该基因表达P210bcr/abl融合蛋白具
Chronic myeloid leukemia (CML) is a malignant clonal disease that originates from hematopoietic stem cells. Approximately 90% to 95% of CML patients have the Philadelphia chromosome (Philadelphia, Ph) and are based on the molecular basis of the c-abl gene on chromosome 9 that translocates to the bcr gene on chromosome 22 to form a new gene chimera-bcr / abl fusion gene, ie t (9; 22) (q34; q11). This gene expresses the P210bcr / abl fusion protein